Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.

Godi A, Kemp TJ, Pinto LA, Beddows S.

J Infect Dis. 2019 Aug 15. pii: jiz401. doi: 10.1093/infdis/jiz401. [Epub ahead of print]

PMID:
31412122
2.

Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.

Godi A, Panwar K, Haque M, Cocuzza CE, Andrews N, Southern J, Turner P, Miller E, Beddows S.

Vaccine. 2019 Apr 24;37(18):2455-2462. doi: 10.1016/j.vaccine.2019.03.052. Epub 2019 Mar 27.

PMID:
30926298
3.

Epidemiology of genital warts in the British population: implications for HPV vaccination programmes.

Sonnenberg P, Tanton C, Mesher D, King E, Beddows S, Field N, Mercer CH, Soldan K, Johnson AM.

Sex Transm Infect. 2019 Aug;95(5):386-390. doi: 10.1136/sextrans-2018-053786. Epub 2019 Feb 5.

4.

Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.

Godi A, Bissett SL, Masloh S, Fleury M, Li S, Zhao Q, Xia N, Cocuzza CE, Beddows S.

J Gen Virol. 2019 Feb;100(2):237-245. doi: 10.1099/jgv.0.001213. Epub 2019 Jan 18.

PMID:
30657447
5.

The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.

Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, Soldan K.

J Infect Dis. 2018 Aug 14;218(6):911-921. doi: 10.1093/infdis/jiy249.

PMID:
29917082
6.

Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies.

Godi A, Martinelli M, Haque M, Li S, Zhao Q, Xia N, Cocuzza CE, Beddows S.

J Infect Dis. 2018 Oct 5;218(10):1611-1621. doi: 10.1093/infdis/jiy354.

PMID:
29905865
7.

Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance.

Louie KS, Dalel J, Reuter C, Bissett SL, Kleeman M, Ashdown-Barr L, Banwait R, Godi A, Sasieni P, Beddows S.

mSphere. 2018 May 9;3(3). pii: e00043-18. doi: 10.1128/mSphere.00043-18. eCollection 2018 May-Jun.

8.

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.

Pinto LA, Dillner J, Beddows S, Unger ER.

Vaccine. 2018 Aug 6;36(32 Pt A):4792-4799. doi: 10.1016/j.vaccine.2017.11.089. Epub 2018 Feb 1.

9.

Sexually active students' acceptability of providing saline oral samples for future human papillomavirus testing.

Williamson J, Fleming C, KerryBarnard S, Monahan I, Planche T, Oakeshott P, Panwar K, Baldie K, Beddows S, Hay PE.

Int J STD AIDS. 2017 Dec;28(14):1464-1465. doi: 10.1177/0956462417736432. Epub 2017 Oct 23. No abstract available.

PMID:
29059030
10.

Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.

Godi A, Bissett SL, Miller E, Beddows S.

J Gen Virol. 2017 Jul;98(7):1755-1761. doi: 10.1099/jgv.0.000829. Epub 2017 Jul 8.

PMID:
28691664
11.

Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis.

Bissett SL, Godi A, Jit M, Beddows S.

Vaccine. 2017 Jul 13;35(32):3922-3929. doi: 10.1016/j.vaccine.2017.06.028. Epub 2017 Jun 17. Review.

12.

Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types.

Tanton C, Mesher D, Beddows S, Soldan K, Clifton S, Panwar K, Field N, Mercer CH, Johnson AM, Sonnenberg P.

Papillomavirus Res. 2017 Jun;3:36-41. doi: 10.1016/j.pvr.2017.01.001.

13.
14.

Trichomonas vaginalis infection is uncommon in the British general population: implications for clinical testing and public health screening.

Field N, Clifton S, Alexander S, Ison CA, Khanom R, Saunders P, Hughes G, Heath L, Beddows S, Mercer CH, Tanton C, Johnson AM, Sonnenberg P.

Sex Transm Infect. 2018 May;94(3):226-229. doi: 10.1136/sextrans-2016-052660. Epub 2016 Sep 29.

15.

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.

Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL.

Emerg Infect Dis. 2016 Oct;22(10):1732-40. doi: 10.3201/eid2210.160675. Review.

16.

Oral Human Papillomavirus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis.

King EM, Oomeer S, Gilson R, Copas A, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg P.

PLoS One. 2016 Jul 6;11(7):e0157976. doi: 10.1371/journal.pone.0157976. eCollection 2016. Review.

17.

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.

Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K.

BMJ Open. 2016 Feb 11;6(2):e009915. doi: 10.1136/bmjopen-2015-009915.

18.

Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.

Godi A, Facchetti A, Bissett SL, Cocuzza C, Miller E, Beddows S.

J Virol. 2015 Dec 30;90(6):3247-52. doi: 10.1128/JVI.02859-15.

19.

Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Sonnenberg P, Ison CA, Clifton S, Field N, Tanton C, Soldan K, Beddows S, Alexander S, Khanom R, Saunders P, Copas AJ, Wellings K, Mercer CH, Johnson AM.

Int J Epidemiol. 2015 Dec;44(6):1982-94. doi: 10.1093/ije/dyv194.

20.

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.

Godi A, Bissett SL, Miller E, Beddows S.

PLoS One. 2015 Oct 23;10(10):e0140926. doi: 10.1371/journal.pone.0140926. eCollection 2015.

21.

Male Circumcision and STI Acquisition in Britain: Evidence from a National Probability Sample Survey.

Homfray V, Tanton C, Miller RF, Beddows S, Field N, Sonnenberg P, Wellings K, Panwar K, Johnson AM, Mercer CH.

PLoS One. 2015 Jun 17;10(6):e0130396. doi: 10.1371/journal.pone.0130396. eCollection 2015.

22.

Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Bissett SL, Godi A, Fleury MJ, Touze A, Cocuzza C, Beddows S.

J Virol. 2015 Aug;89(15):7748-57. doi: 10.1128/JVI.00842-15. Epub 2015 May 20.

23.

Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance.

King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Jit M, Edmunds WJ, Sonnenberg P.

Sex Transm Infect. 2015 Jun;91(4):284-6. doi: 10.1136/sextrans-2014-051955. Epub 2015 Apr 17.

24.

Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies.

King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Prah P, Jit M, Edmunds WJ, Sonnenberg P.

Br J Cancer. 2015 Apr 28;112(9):1585-93. doi: 10.1038/bjc.2015.90. Epub 2015 Mar 19.

25.

Amino acid motifs in both the major and minor capsid proteins of HPV51 impact antigenicity and infectivity.

Godi A, Epifano I, Bissett SL, Dell'Anna T, Piana A, Cocuzza C, Beddows S.

J Gen Virol. 2015 Jul;96(Pt 7):1842-9. doi: 10.1099/vir.0.000121. Epub 2015 Mar 13.

PMID:
25770119
26.

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M.

Lancet Infect Dis. 2015 May;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4. Epub 2015 Mar 3. Review.

27.

High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.

Tanton C, Soldan K, Beddows S, Mercer CH, Waller J, Field N, Clifton S, Copas AJ, Panwar K, Manyenga P, da Silva F, Wellings K, Ison CA, Johnson AM, Sonnenberg P.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):842-53. doi: 10.1158/1055-9965.EPI-14-1333. Epub 2015 Mar 3.

28.

Confirmatory assays are essential when using molecular testing for Neisseria gonorrhoeae in low-prevalence settings: insights from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Field N, Clifton S, Alexander S, Ison CA, Hughes G, Beddows S, Tanton C, Soldan K, Coelho da Silva F, Mercer CH, Wellings K, Johnson AM, Sonnenberg P.

Sex Transm Infect. 2015 Aug;91(5):338-41. doi: 10.1136/sextrans-2014-051850. Epub 2014 Dec 15.

29.

Is dexmedetomidine more effective than remifentanil for neurologic outcomes in patients undergoing CEA surgery using regional anesthesia?

Carter R, Richardson A, Santoro J, Beddows S, McCarthy EJ.

J Perianesth Nurs. 2014 Dec;29(6):466-74. doi: 10.1016/j.jopan.2014.07.001. Epub 2014 Nov 20.

PMID:
25458626
30.

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.

Bissett SL, Mattiuzzo G, Draper E, Godi A, Wilkinson DE, Minor P, Page M, Beddows S.

Vaccine. 2014 Nov 12;32(48):6548-55. doi: 10.1016/j.vaccine.2014.07.116. Epub 2014 Sep 6.

31.

Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage.

Marongiu L, Godi A, Parry JV, Beddows S.

BMC Cancer. 2014 May 30;14:384. doi: 10.1186/1471-2407-14-384.

32.

Human papillomavirus type 16 long control region and E6 variants stratified by cervical disease stage.

Marongiu L, Godi A, Parry JV, Beddows S.

Infect Genet Evol. 2014 Aug;26:8-13. doi: 10.1016/j.meegid.2014.05.009. Epub 2014 May 10.

33.

Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Bissett SL, Draper E, Myers RE, Godi A, Beddows S.

Vaccine. 2014 Feb 26;32(10):1139-46. doi: 10.1016/j.vaccine.2014.01.008. Epub 2014 Jan 15.

34.

Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal).

Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, Mercer CH, da Silva FC, Alexander S, Copas AJ, Phelps A, Erens B, Prah P, Macdowall W, Wellings K, Ison CA, Johnson AM.

Lancet. 2013 Nov 30;382(9907):1795-806. doi: 10.1016/S0140-6736(13)61947-9. Epub 2013 Nov 26.

35.

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.

Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, Beddows S, Gill ON.

Vaccine. 2013 Dec 17;32(1):26-32. doi: 10.1016/j.vaccine.2013.10.085. Epub 2013 Nov 6.

36.

Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.

Ahmed AI, Bissett SL, Beddows S.

Infect Genet Evol. 2013 Aug;18:151-9. doi: 10.1016/j.meegid.2013.05.013. Epub 2013 May 27.

37.

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.

Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.

PLoS One. 2013 May 1;8(5):e61825. doi: 10.1371/journal.pone.0061825. Print 2013.

38.

Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study.

Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, Lacey CJ, Beddows S, Soldan K.

BMJ. 2012 Jun 22;344:e4168. doi: 10.1136/bmj.e4168.

39.

Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer.

Cescon DW, Ganz PA, Beddows S, Ennis M, Mills BK, Goodwin PJ.

Breast Cancer Res Treat. 2012 Jul;134(2):759-67. doi: 10.1007/s10549-012-2120-7. Epub 2012 Jun 16.

PMID:
22706631
40.

Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation.

Howell-Jones R, de Silva N, Akpan M, Oakeshott P, Carder C, Coupland L, Sillis M, Mallinson H, Ellis V, Frodsham D, Robinson TI, Gill ON, Beddows S, Soldan K.

Vaccine. 2012 Jun 6;30(26):3867-75. doi: 10.1016/j.vaccine.2012.04.006. Epub 2012 Apr 16.

41.

Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.

Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, Lewis DJ.

PLoS One. 2012;7(3):e33736. doi: 10.1371/journal.pone.0033736. Epub 2012 Mar 16.

42.

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1.

Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ.

Breast Cancer Res Treat. 2012 Jun;133(3):1077-88. doi: 10.1007/s10549-012-2012-x. Epub 2012 Mar 14. Erratum in: Breast Cancer Res Treat. 2012 Oct;135(3):923.

43.

Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.

Bissett SL, Wilkinson D, Tettmar KI, Jones N, Stanford E, Panicker G, Faust H, Borrow R, Soldan K, Unger ER, Dillner J, Minor P, Beddows S.

Clin Vaccine Immunol. 2012 Mar;19(3):449-51. doi: 10.1128/CVI.05641-11. Epub 2012 Jan 25.

44.

Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain.

Johnson AM, Mercer CH, Beddows S, de Silva N, Desai S, Howell-Jones R, Carder C, Sonnenberg P, Fenton KA, Lowndes C, Soldan K.

Sex Transm Infect. 2012 Apr;88(3):212-7. doi: 10.1136/sextrans-2011-050306. Epub 2012 Jan 17.

45.

Testing for sexually transmitted infections in a population-based sexual health survey: development of an acceptable ethical approach.

Field N, Tanton C, Mercer CH, Nicholson S, Soldan K, Beddows S, Ison C, Johnson AM, Sonnenberg P.

J Med Ethics. 2012 Jun;38(6):380-2. doi: 10.1136/medethics-2011-100068. Epub 2012 Jan 17.

46.

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.

Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, Soldan K, Beddows S.

Vaccine. 2011 Nov 3;29(47):8585-90. doi: 10.1016/j.vaccine.2011.09.021. Epub 2011 Sep 21.

47.

Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males.

Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M, Soldan K, Szarewski A, Cuzick J, Beddows S.

J Med Virol. 2011 Oct;83(10):1744-51. doi: 10.1002/jmv.22167. Erratum in: J Med Virol. 2011 Dec;83(12):2237.

PMID:
21837790
48.

Weighing up the SEF.

Upton P, Taylor C, Beddows S, Upton D.

Community Pract. 2010 Jul;83(7):34-5. No abstract available.

PMID:
20701190
49.

Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England.

Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H; Study Group Collaborators.

Br J Cancer. 2010 Jul 13;103(2):209-16. doi: 10.1038/sj.bjc.6605747. Erratum in: Br J Cancer. 2010 Sep 7;103(6):928.

50.

DNA methylation analysis in liquid-based cytology for cervical cancer screening.

Apostolidou S, Hadwin R, Burnell M, Jones A, Baff D, Pyndiah N, Mould T, Jacobs IJ, Beddows S, Kocjan G, Widschwendter M.

Int J Cancer. 2009 Dec 15;125(12):2995-3002. doi: 10.1002/ijc.24745.

Supplemental Content

Loading ...
Support Center